Therapy insight: Management of hepatorenal syndrome. (Q34533221)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16741553 AND SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

Therapy insight: Management of hepatorenal syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16741553 AND SRC:MED&resulttype=core&format=json

29 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16741553 AND SRC:MED&resulttype=core&format=json

29 January 2020

Pere Ginès

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16741553 AND SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Andrés Cárdenas

series ordinal

1

1 reference

2 August 2017

Pere Ginès

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16741553 AND SRC:MED&resulttype=core&format=json

Nature Reviews Gastroenterology & Hepatology

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16741553 AND SRC:MED&resulttype=core&format=json

29 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16741553 AND SRC:MED&resulttype=core&format=json

29 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16741553 AND SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

338-348

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16741553 AND SRC:MED&resulttype=core&format=json

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Management of cirrhosis and ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Renal failure in the patient with cirrhosis. The role of active vasoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Circulatory function and hepatorenal syndrome in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Assessing renal function in cirrhotic patients: problems and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Hepatorenal syndrome: a dreaded complication of end-stage liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Effects of contrast media on renal function in patients with cirrhosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Management of complications of cirrhosis in patients awaiting liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Improvement in renal function in hepatorenal syndrome with N-acetylcysteine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

The Clinical Course of Patients with Type 1 Hepatorenal Syndrome Maintained on Hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Risk Factors and Outcome of 107 Patients with Decompensated Liver Disease and Acute Renal Failure (Including 26 Patients with Hepatorenal Syndrome): The Role of Hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

The Prometheus device for extracorporeal support of combined liver and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

Renal failure in acute liver failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Renal Failure in Patients With Cirrhosis and Sepsis Unrelated to Spontaneous Bacterial Peritonitis: Value of MELD Score

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Hepatorenal syndrome--is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction?

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Hepatorenal Syndrome in Cirrhosis: Clinical Features, Diagnosis, and Management

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Amelioration of hepatorenal syndrome with selective endothelin-A antagonist

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems

1 reference

https://api.crossref.org/works/10.1038/NCPGASTHEP0517

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP0517

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16741553 AND SRC:MED&resulttype=core&format=json

29 January 2020

1 reference